A reference for psychedelic medicine, mental health and healing. Written for physicians, researchers, individuals and families who want to understand what these medicines are, what is being studied, and what questions to ask before a decision.
Each entry brings together origins, mechanisms, potential benefits investigated, important risks and legal context. Follow the citations to published research and official sources. Traditional knowledge, personal accounts and clinical evidence are presented as different kinds of understanding, not interchangeable proof.
11Medicine entries
14Research topics
40Linked source records
OpenEducational access
RESEARCH ASSISTANT
Ask the Doc. Start with your question.
Explore medicine, research, preparation or interactions in plain language or professional depth. The assistant is AI, not a doctor or a substitute for qualified care.
Opens the dedicated Ask the Doc page for review before you submit. Your question is not placed in the web address.
Medicines & Substances
Each entry includes origin, mechanism of action, research findings, risks, medication questions, legal context and source links. Research topics are not approved indications or a statement that a medicine is suitable for you.
Addiction & trauma research
Ibogaine
Derived from iboga alkaloids
Ibogaine is a psychoactive indole alkaloid derived from Tabernanthe iboga, a West-Central African shrub. Modern research has focused mainly on opioid withdrawal and substance-use disorders. Small observational studies report rapid reductions in withdrawal symptoms and, for some participants, reduced or stopped opioid use; depressive symptoms have also improved in some follow-ups. These findings are promising but not proof of efficacy: the evidence base is small, heterogeneous, often uncontrolled, and includes serious medical complications and deaths. A systematic review found 24 clinical studies involving 705 people, including only a small number of controlled trials [1]. A 12-month observational study reported improvement among a small cohort, but one participant died during treatment and only eight completed all follow-ups [2]. Ibogaine is not presented here as a cure or as personal treatment advice.
Ibogaine is converted in the body, primarily by CYP2D6, to noribogaine, which remains active for longer. Laboratory and animal research indicate effects across several systems, including opioid, serotonin, NMDA, and sigma-related signaling; no single mechanism explains the reported changes in withdrawal, craving, perception, and mood. Human pharmacology is variable because CYP2D6 genetics and interacting medicines can alter exposure. Ibogaine and noribogaine also affect cardiac ion channels, helping explain QT-interval prolongation and arrhythmia risk [3]. Mechanistic plausibility is not clinical proof.
Research finding in context
Investigational; not an established treatment
Acute reduction in opioid-withdrawal symptoms
Open-label and observational studies report lessened withdrawal after administration. This signal is clinically interesting, but expectancy, selection, concurrent care, and the absence of robust published randomized efficacy results limit interpretation [1][2].
Evidence limit: Preliminary human evidence; not established care.
Ibogaine can prolong the QT interval, slow heart rate, and in susceptible circumstances contribute to torsades de pointes, ventricular arrhythmia, cardiac arrest, or death. A monitored observational study found clinically relevant QTc prolongation even in screened participants [3].
Read interaction considerations
Ibogaine and noribogaine are metabolized through pathways that include CYP2D6, while ibogaine can affect cardiac repolarization. Medicines or substances that prolong QT, alter CYP2D6 or other relevant enzymes, depress the central nervous system, or change opioid tolerance may increase risk. Combining ibogaine with opioids, stimulants, alcohol, serotonergic medicines, or unverified supplements is not predictable. Interaction review requires a qualified clinician and an ECG- and medical-monitoring plan; this entry does not provide a washout schedule or combination protocol.
Legal and regulatory context
Legal status varies substantially by country and sometimes by state or province. In the United States, ibogaine is not FDA-approved; FDA describes psychedelic work as drug development and notes that allowing an early-phase noribogaine study to proceed is not an approval of safety or effectiveness [4]. ClinicalTrials.gov lists an ibogaine Phase 1/2 study for opioid withdrawal as completed, while noting that registry listing is not government approval [4]. Laws elsewhere change, and possession, import, administration, and clinical research may be regulated differently; check current official local rules.
Ketamine is a dissociative anesthetic used in human. It alters perception, attention, pain, memory, and sense of self. In the United States, the related medicine esketamine (the S-enantiomer) is FDA-approved for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in both cases under a restricted, supervised program and with an oral antidepressant for the latter. The label says it has not been shown to prevent suicide [1]. Racemic ketamine infusions for depression are not FDA-approved for that indication and are an off-label clinical practice. Early trials reported rapid but usually brief improvement in some adults; long-term benefit and safety remain uncertain [3]. This is education, not personal treatment advice or clinician review.
Ketamine and esketamine are non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists [1]. By changing glutamate signaling and downstream plasticity pathways, ketamine may temporarily alter mood, threat, pain, and perception circuits; its antidepressant mechanism is not settled. Dissociation is not proof of spiritual transformation. Studies mostly enroll adults with diagnosed depression after other treatments and often exclude cardiovascular disease, psychosis, and substance-use risk. Findings cannot be generalized to every diagnosis, age group, culture, or setting [3].
Research finding in context
Established anesthetic; esketamine approved for specific adult depression indications; racemic ketamine depression use remains off-label
Rapid reduction of depressive symptoms in some treatment-resistant adults
Controlled studies of intravenous racemic ketamine found improvement can begin within about a day, with benefit commonly measured over a short window. Esketamine trials support a role for selected adults with treatment-resistant depression, but response is variable and does not establish a permanent effect [1][3].
Evidence limit: Randomized trials and reviews in studied adults; not evidence for unsupervised use.
Perceptual changes, detachment, dizziness, nausea, anxiety, confusion, and impaired motor skills can occur. Supervised esketamine requires observation because sedation, dissociation, and respiratory depression may occur [1].
Read interaction considerations
Alcohol, opioids, benzodiazepines, sleep medicines, and other central-nervous-system depressants can compound sedation and breathing risk. Medicines or conditions that raise blood pressure, and drugs affecting alertness, may alter risk; the FDA label also notes clinically relevant interaction considerations for central depressants, psychostimulants, and monoamine oxidase inhibitors [1]. A prescriber should review medicines, substances, pregnancy, and health history. Do not stop or combine medicines based on this entry.
Legal and regulatory context
In the United States, ketamine is a Schedule III controlled substance [4]. Ketamine is FDA-approved as an anesthetic, while esketamine has the specific adult depression indications described above; racemic ketamine for depression is off-label [1][2]. Prescribing and supervised-service rules vary and change. Check the current law and regulator guidance where you live; legality is not safety evidence.
Psilocybin is a naturally occurring compound in some fungi. The body converts it to psilocin, which can alter perception, emotion, memory, time sense, and self-experience. Research is investigating psilocybin-assisted therapy for depression, alcohol use disorder, anxiety and existential distress in serious illness, PTSD, and other conditions; it is not a general-purpose wellness treatment. In supervised trials, the medicine is paired with preparation, psychological support, and follow-up rather than treated as a stand-alone cure. Early findings are encouraging but studies are often small, difficult to blind, short, and conducted with carefully screened adults. A 2023 review of five depression studies (215 participants) found symptom reduction through about five weeks, while comparative evidence has not established superiority to standard care. [1]
Psilocin primarily stimulates serotonin 5-HT2A receptors, especially in cortical networks involved in perception, cognition, and meaning-making. This receptor activity is associated with acute changes in sensory processing and flexible or unusual patterns of brain activity; psychological effects are also shaped by expectations, mood, surroundings, prior experience, and support. Proposed mechanisms include increased emotional learning and a period of heightened plasticity, but these remain active research questions, not settled explanations or guarantees of benefit. [1][2]
Research finding in context
Investigational; promising but limited evidence
Depression symptom relief
Randomized and review evidence suggests that one or more supported sessions may reduce depressive symptoms in the short to medium term for some adults, including people with major depressive disorder. Durability beyond the studied follow-up periods and comparative effectiveness remain uncertain; one trial did not find better symptom reduction than escitalopram plus psychological support. [1]
Evidence limit: Promising early randomized evidence; small samples, expectancy and blinding challenges, selected participants, and limited long-term data.
Experiences can be unpredictable and may include fear, panic, confusion, paranoia, disturbing memories, impaired judgment, or hallucinations. Persistent psychosis has been reported. People with schizophrenia, schizoaffective disorder, or severe bipolar disorder should not use psilocybin; screening and a controlled setting matter in research. [1]
Read interaction considerations
Interaction studies remain incomplete, including with SSRIs and other psychiatric, migraine, pain, or serotonergic medicines. Alcohol and other psychoactive substances may make effects less predictable and can increase impairment. A qualified healthcare professional should review all medicines, supplements, cardiovascular history, and mental-health history; this entry does not recommend a washout, combination, or dosing plan. [1]
Legal and regulatory context
As of this review date, FDA describes psychedelic drugs as under active development and provides guidance for clinical investigations; that is not approval of psilocybin for depression, addiction, or another condition. In the United States, NCCIH reports that DEA lists psilocybin as Schedule I federally, while some states and the District of Columbia have decriminalized or deprioritized possession and some jurisdictions have specific supervised-service laws. Rules differ by country and can change; verify current local law. [2][3]
Ayahuasca is a psychoactive botanical brew traditionally made from Banisteriopsis caapi and a DMT-containing plant such as Psychotria viridis. Indigenous peoples of the Amazon have used related brews in healing, spiritual, and community life for generations; Brazilian syncretic churches later developed their own ritual traditions. In contemporary research, ayahuasca is being studied—not prescribed—as a possible aid for depression and other conditions. A small randomized, placebo-controlled trial in adults with treatment-resistant, unipolar depression found rapid symptom improvement after one supervised session, but its sample was small, follow-up was brief, and participants with bipolar disorder, psychotic disorders, significant medical illness, substance misuse, and suicidality were excluded [1]. This is promising but cannot establish effectiveness or safety for the general public, and it is not personal treatment advice.
DMT is a serotonergic psychedelic that also acts at sigma-1 receptors; the harmala alkaloids in B. caapi reversibly inhibit monoamine oxidase, allowing orally consumed DMT to become active. Together they can produce intense changes in perception, emotion, cognition, time, and sense of self, commonly lasting several hours [1, 2]. Human findings are compatible with acute changes in brain systems involved in mood and self-processing, but the full mechanism—and whether biological effects explain longer-term outcomes—remains unsettled. Research on ayahuasca is not interchangeable with research on isolated DMT or other psychedelics.
Research finding in context
Investigational; not an approved medicine in the United States
Depressive symptoms
The controlled trial reported greater short-term reduction in depression ratings than placebo in carefully screened adults with treatment-resistant unipolar depression. Earlier open-label work also suggested improvement, but expectancy, setting, and regression to the mean are difficult to separate from drug effects [1].
Evidence limit: Early clinical signal; replication with larger samples, active/placebo controls, longer follow-up, and diverse populations is needed.
Nausea, vomiting, diarrhea, dizziness, agitation, increased heart rate, and elevated blood pressure can occur. DMT toxicity reports include seizures, loss of coordination, coma, and respiratory arrest; serious events are uncommon in screened research settings but real-world preparations and health conditions vary [2, 4].
Read interaction considerations
Harmala alkaloids inhibit monoamine oxidase, so combinations with serotonergic, sympathomimetic, stimulant, or other psychoactive medicines can produce unpredictable or dangerous effects, including severe blood-pressure changes, agitation, seizures, or serotonin toxicity. Evidence is incomplete and product composition varies. Do not stop or alter prescribed medicines based on this page; ask a qualified clinician or pharmacist who can review the complete medication, supplement, and health history.
Legal and regulatory context
Legal status varies by country, state, and religious or ceremonial facts. In the United States, DMT is controlled in Schedule I and has no approved medical use according to the DEA [4]; ayahuasca may therefore present serious legal risk, although litigation and limited religious protections are fact-specific. Brazil recognizes ritual use in a particular regulatory history, but laws change. Check current official law where you are; legality is not evidence of safety or efficacy.
N,N-dimethyltryptamine (DMT) is a naturally occurring tryptamine and classic serotonergic psychedelic. Depending on the preparation and route, it can rapidly alter perception, emotion, sense of self, and time [1]. Intravenous research in healthy adults found intense effects that peaked within minutes and resolved quickly after administration stopped, but the study was small and did not test treatment of a disorder [2]. DMT remains an investigational subject rather than an established treatment; a current Yale registry entry describes a recruiting, Phase 1 placebo-controlled study of DMT plus psychotherapy for alcohol use disorder, with no results posted [3]. Claims of durable benefit should therefore be treated as hypotheses, not conclusions.
DMT acts at several serotonin receptors, with 5-HT2A activation understood as central to the psychedelic experience; it also interacts with serotonin transport and other receptor systems. When taken orally by itself, it is rapidly broken down by monoamine oxidase (MAO), which helps explain its route-dependent duration. Ayahuasca is a distinct preparation: plant beta-carbolines inhibit MAO and increase oral DMT bioavailability. A systematic review found that the precise interactions may be additive or synergistic and remain incompletely understood [4]. Mechanistic findings do not by themselves establish safety or therapeutic effectiveness.
Research finding in context
Investigational; not established clinical treatment
A research tool for understanding conscious experience
DMT can produce a short, controllable psychedelic state in laboratory settings, allowing researchers to study perception, self-processing, and brain-body responses. This is a scientific use, not evidence that unsupervised use is safe or beneficial.
Evidence limit: The randomized crossover study included 27 healthy adults with limited lifetime psychedelic exposure; it measured acute effects and pharmacokinetics, not clinical outcomes [2].
The experience can be overwhelming, with fear, anxiety, disorientation, altered reality testing, or difficult memories. People with a history of psychosis, mania, or serious instability may face particular concern; vulnerability screening is essential in research. Persistent distress or psychotic symptoms require urgent professional help.
Read interaction considerations
DMT-containing ayahuasca combines DMT with MAO-inhibiting beta-carbolines, which changes duration and exposure. The systematic review emphasizes that the pharmacology is not fully understood and describes concern about interactions with serotonergic medicines [4]. Combining DMT or ayahuasca with antidepressants, MAO inhibitors, stimulants, other psychoactive substances, or medicines affecting blood pressure can be hazardous; serotonin toxicity, hypertensive reactions, or altered metabolism are clinical concerns. Do not stop or change prescribed medicines to use a psychedelic. A qualified clinician or pharmacist should review every medicine, supplement, and health condition; this entry gives no washout or combination protocol.
Legal and regulatory context
Laws vary by country, state, territory, and religious or research exemption. In the United States, the current eCFR lists dimethyltryptamine (DMT) in Schedule I [6], while a ClinicalTrials.gov record shows that regulated research can still occur [3]. This is not legal advice; possession, preparation, administration, and importation may be separately regulated, and local rules can change. Verify current law with an authoritative local source.
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a potent psychedelic tryptamine found in some plants and in the secretion of the Sonoran Desert toad, Incilius alvarius (formerly Bufo alvarius). “Bufo” is not a standardized medicine: toad secretion contains 5-MeO-DMT plus other biologically active compounds, including cardiac glycosides and catecholamines, with variable composition [2]. Synthetic 5-MeO-DMT is distinct from whole secretion. Effects can begin rapidly and include major changes in perception, emotion, body awareness, and sense of self. Human therapeutic evidence remains preliminary: a 2024 systematic review found only three eligible clinical trials with 78 participants, two in healthy volunteers and one in treatment-resistant depression, with short follow-up and no serious adverse events [1]. These findings do not establish efficacy or safety for the general public.
The compound primarily activates serotonin 5-HT1A and 5-HT2A receptors, with additional serotonin-system activity; its active metabolite bufotenine is formed partly through CYP2D6 metabolism. MAO-A is an important inactivation pathway [2]. These mechanisms may alter network activity and emotional processing, but proposed neuroplastic, anti-inflammatory, or antidepressant effects remain hypotheses rather than established clinical mechanisms. Intense, short-lived experiences may include ego dissolution and mystical-type phenomena; these are descriptions of subjective experience, not proof of therapeutic benefit.
Research finding in context
Investigational; limited early human evidence
Rapid changes in mood symptoms
Early studies and surveys have reported reductions in depression, anxiety, and stress after naturalistic use, and a small early-phase program has studied people with treatment-resistant depression. Findings cannot separate drug effects from expectancy, selection, context, or post-session support [1][2].
Evidence limit: Preliminary observational and early-phase evidence; efficacy is not established.
Clinical studies observed transient increases in heart rate and blood pressure, with headache, nausea, chest discomfort, and other physical effects reported [1]. Toad secretion adds variable cardioactive compounds, so its risk profile cannot be inferred from purified synthetic material [2].
Read interaction considerations
Potentially dangerous interactions include MAO inhibitors, serotonergic medicines or supplements, stimulants, and drugs affecting blood pressure, heart rhythm, or CYP2D6 metabolism. The evidence base does not define universally safe combinations or waiting periods. A qualified clinician or pharmacist who knows the complete medication, supplement, and health history is the appropriate source for individualized risk review; this entry is not a treatment protocol.
Legal and regulatory context
In the United States, the DEA’s 2024 resource guide lists 5-MeO-DMT as a Schedule I controlled substance [3]. Laws differ by country, state, territory, and sometimes by source material; possession, preparation, administration, importation, and facilitation may carry separate consequences. ClinicalTrials.gov records 5-MeO-DMT studies as research, not as proof of regulatory approval; the cited phase 1 study was not an FDA-regulated drug product [4]. Check current official law where you live.
Lysergic acid diethylamide (LSD) is a potent classic psychedelic that can markedly alter perception, emotion, time sense, self-experience, and judgment. Effects can be unpredictable and may include both wonder and fear. Modern clinical research is small compared with research on established medicines, and results from carefully screened, supported participants should not be generalized to unsupervised use. A systematic review found 11 randomized trials involving 567 patients, many conducted decades ago with heterogeneous methods; the most encouraging historical signal was short-term improvement in alcohol-related problems, while longer-term results often converged with control groups and overall evidence remained limited [1]. LSD is not FDA-approved for any medical condition; NIDA describes psychedelic treatments as an active research area, with studies conducted under medical supervision and usually alongside psychotherapy [2].
LSD acts primarily as a serotonin 5-HT2A receptor agonist, with downstream effects across cortical networks involved in perception, salience, cognition, and self-processing. The subjective experience is shaped not only by pharmacology but also by expectations, environment, psychological state, and support. Its long duration can make distress difficult to contain once it begins. Proposed neuroplasticity and psychological mechanisms remain hypotheses under study rather than established explanations of clinical benefit [1][2].
Research finding in context
Investigational evidence; no FDA-approved therapeutic indication
Alcohol-use outcomes
Older controlled studies summarized in a systematic review suggest LSD-assisted approaches may reduce alcohol-related symptoms or drinking in some participants, particularly in the short term. These findings came from structured research settings, not general self-treatment, and durability was inconsistent.
Evidence limit: Promising but limited and historically heterogeneous; contemporary, well-controlled replication is needed.
Anxiety, panic, dysphoria, confusion, paranoia, impaired judgment, and frightening perceptual changes can occur. In uncontrolled settings, altered judgment can increase risk of injury; severe or prolonged reactions require urgent medical assessment [1][3].
Read interaction considerations
Interactions are not fully characterized in clinical research. Combining LSD with other psychoactive, serotonergic, stimulant, or blood-pressure-active substances may make effects less predictable and can complicate emergency assessment. Prescribed medicines, psychiatric history, seizure risk, cardiovascular conditions, pregnancy, and sleep deprivation should be discussed with a qualified clinician; do not stop or change medicines to pursue psychedelic use.
Legal and regulatory context
In the United States, the DEA lists LSD as a Schedule I substance, defined federally as having high abuse potential and no currently accepted medical use; possession, manufacture, and distribution are generally illegal outside authorized research [4]. Laws vary by country, state, territory, and local policy, and may change. Investigational research authorization is not the same as approval for routine clinical treatment. Check current official law where you live.
Iboga is a Central African shrub (Tabernanthe iboga); ibogaine is its principal psychoactive indole alkaloid and noribogaine is a major active metabolite. Contemporary research has focused mainly on opioid use disorder (OUD), with smaller observational work involving other substance-use problems and psychological symptoms. A systematic review found 24 clinical studies including 705 people, but only a small minority were randomized controlled trials; most were open-label studies, case series, surveys, or case reports [1]. Reported reductions in withdrawal symptoms and craving are promising signals, not proof of durable recovery or superiority to established care. In the United States, FDA materials describe ongoing psychedelic-drug development rather than an approved ibogaine medicine [5]. NIDA identifies methadone, buprenorphine, and naltrexone as FDA-approved medications for OUD, with lofexidine helping withdrawal symptoms [4].
Ibogaine and noribogaine act across several systems rather than through one established pathway. Reviews describe modulation of opioid, serotonin, glutamate/NMDA, sigma, and nicotinic acetylcholine targets, while emphasizing that the clinically relevant anti-addictive mechanism remains uncertain [3]. Noribogaine may contribute substantially after ibogaine is metabolized. Ibogaine also inhibits cardiac hERG potassium channels, slowing ventricular repolarization and helping explain QT prolongation and arrhythmia risk [2]. Mechanistic findings from cells and animals cannot be assumed to predict benefit or safety in a particular person.
Research finding in context
Investigational; early and limited clinical evidence
Rapid reduction of opioid withdrawal and craving
Small clinical studies and observational reports describe less acute opioid withdrawal and craving after administration. The evidence is heterogeneous, often uncontrolled, and vulnerable to selection, expectancy, and follow-up bias; it does not establish sustained abstinence or replacement of evidence-based OUD care [1].
Evidence limit: Early signal; insufficient for clinical efficacy conclusions
QTc prolongation, bradycardia, torsades de pointes, cardiac arrest, and death have been reported. In a 14-person monitored observational study, all had severe transient ataxia and half exceeded a QTc of 500 ms; no torsades occurred in that small, screened sample [2].
Read interaction considerations
Risk may increase with other QT-prolonging medicines, drugs that slow heart rate, electrolyte disturbances, or medicines and supplements that alter CYP2D6 metabolism. Serotonergic and other psychoactive combinations may also be unpredictable. Clinical studies commonly excluded QT-prolonging or CYP2D6-affecting medicines and screened out many CNS drugs [2, 6]. Do not stop, substitute, or combine prescribed treatment based on this entry; a qualified clinician or pharmacist must review the complete medication and health history.
Legal and regulatory context
Legal status varies by jurisdiction and can change. As of the DEA's August 27, 2026 list, ibogaine is a U.S. federal Schedule I controlled substance (drug code 7260) [7]. FDA's current public materials describe research and an early-phase noribogaine study, not approval of ibogaine for OUD or any other condition [5]. Possession, use, importation, and ceremonial or clinical access may be regulated differently elsewhere; check the current law and regulator in the relevant location.
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic psychoactive substance with stimulant and prosocial effects. In research, it is paired with preparation, one or more closely supervised medicine sessions, and follow-up psychotherapy; the therapy is not simply taking MDMA. In a 2023 phase 3 randomized trial, 104 adults with moderate or severe PTSD received MDMA-assisted therapy or placebo with the same therapy. PTSD symptoms and functional impairment improved more in the MDMA group at the 18-week endpoint [1]. The participants were ethnoracially diverse, but the sample was small and selected, and expectancy and difficulty maintaining blinding remain important limitations. A systematic review found more short-term side effects than control conditions and judged most trials at high risk of bias, with certainty ranging from very low to moderate [2].
MDMA increases signaling involving serotonin, norepinephrine, and dopamine and can alter arousal, mood, social connection, and perception [3]. Researchers propose that reduced threat responses and increased emotional openness may help some people engage with trauma-focused psychotherapy, while the therapeutic relationship, meaning-making, and repeated integration work are also central. The exact contribution of MDMA versus psychotherapy, expectancy, and selection of participants is not settled; FDA specifically requested better evidence separating these components [4].
Research finding in context
Promising but investigational; evidence is concentrated in structured clinical trials for moderate-to-severe PTSD.
PTSD symptom reduction
In the phase 3 trial, clinician-rated PTSD severity improved more with MDMA-assisted therapy than with therapy plus placebo at 18 weeks; this is an average group finding, not a promise for an individual [1].
Evidence limit: One confirmatory phase 3 trial, supported by earlier studies; durability beyond the study window was not established to FDA's satisfaction [4].
MDMA can raise heart rate and blood pressure and may cause sweating, overheating, nausea, jaw clenching, muscle tightness, chest discomfort, or visual and motor effects. Cardiac safety assessment in the US application was incomplete, and FDA requested dedicated ECG and laboratory evaluation [2][4].
Read interaction considerations
Medication review is essential. Evidence is insufficient to give a universal rule for antidepressants or other medicines: FDA requested a dedicated interaction study, including whether SSRI tapering is necessary, and abrupt medication changes can be harmful [4]. Alcohol, stimulants, serotonergic drugs, and unregulated substances may increase impairment or physiologic risk. Only a qualified clinician who knows a person's medical history can assess interactions.
Legal and regulatory context
Legal status varies by country, state, and territory and can change. In the United States, FDA's 2024 complete response letter stated that the proposed product could not be legally marketed unless and until FDA approval was granted [4]; this entry does not assert approval as of the review date. MDMA remains controlled or otherwise restricted in many jurisdictions, while carefully authorized research may be lawful. Check the current regulator and local law; possession or supply may carry serious penalties.
Mescaline is a psychedelic alkaloid found in peyote (Lophophora williamsii) and some other cacti. It can temporarily change perception, mood, sense of time,. Acute effects may include vivid imagery, altered body awareness, nausea or vomiting, increased heart rate and blood pressure, sweating, headache, anxiety, and impaired coordination [1]. Modern human evidence for mescaline itself is sparse: a completed phase 1 study enrolled only 16 healthy adults, excluded major medical and psychiatric conditions, and posted no results on its registry record [3]. Findings from other psychedelics should not be assumed to apply to mescaline. This entry is education, not personal medical advice.
Mescaline is a classic serotonergic psychedelic. Research is centered on serotonin 5-HT2A receptor signaling, which appears to contribute substantially to psychedelic perception; the registered human study tested this question with the 5-HT2A antagonist ketanserin [3]. Mescaline also affects other serotonin and adrenergic systems, but the relationship between receptor activity, subjective experience, and any lasting clinical change is not fully established. Peyote is a whole cactus containing multiple alkaloids, so its effects and risks may not be identical to purified mescaline.
Research finding in context
Investigational; not an established approved treatment
Meaningful or spiritual experience
People describe peyote ceremonies and mescaline experiences as emotionally significant, perceptually expansive, or spiritually meaningful. These are reported experiences, not proof of medical benefit, and cultural meaning must not be reduced to a clinical outcome.
Evidence limit: Traditional use is longstanding; controlled modern evidence for therapeutic benefit is insufficient.
Acute increases in heart rate and blood pressure, pupil dilation, sweating, elevated temperature, weakness, headache, nausea, and vomiting are documented effects [1]. People with cardiovascular disease or uncontrolled blood pressure may face particular concern; this is not a substitute for individualized medical screening.
Read interaction considerations
Potential interactions depend on the person, preparation, and medicines involved. The phase 1 study excluded medicines that might interfere with study medication and used strict health screening [3], underscoring that interaction safety is not established. Combining mescaline or peyote with psychoactive drugs, serotonin- or blood-pressure-affecting medicines, alcohol, or unknown products may increase cardiovascular, psychiatric, or impairment risks. A qualified clinician or pharmacist should review a complete medication and health list; this page does not provide a combination protocol.
Legal and regulatory context
Legal status varies by country, state, territory, and context. In the United States, 42 U.S.C. §1996a protects an Indian’s use, possession, or transportation of peyote for bona fide traditional ceremonial purposes in a traditional Indian religion, while allowing certain regulation and safety limits [4]. That narrow protection is not a general exemption for mescaline, commercial services, or non-ceremonial use. Check current local law and do not infer legality from another jurisdiction.
San Pedro, often called Huachuma or Wachuma, refers chiefly to mescaline-containing columnar cacti in the Echinopsis (formerly Trichocereus) group. Mescaline is a classic psychedelic: it can substantially alter perception, emotion, time sense, and self-experience. A controlled human study found acute subjective and autonomic effects in healthy adults, with a long experience duration, but it did not test treatment of a disorder. The study excluded people with major psychiatric or physical illness and medication use, so its safety findings cannot be generalized to clinical populations or ceremonial settings [1]. Claims that Huachuma treats depression, trauma, addiction, or other conditions remain investigational; evidence is much thinner than the public conversation often suggests.
Mescaline acts primarily through serotonin 5-HT2A-family signaling, with additional activity at 5-HT2C and other serotonin systems; downstream signaling changes excitatory neurotransmission and perception. Reviews also describe modest dopaminergic effects and rapid tolerance to repeated serotonergic psychedelic exposure [2]. The chemistry of a prepared cactus is variable, and plant material contains compounds beyond isolated mescaline. Effects therefore cannot be inferred reliably from a label, appearance, or another person’s experience.
Research finding in context
Investigational and culturally significant; not an established medical treatment
Acute perspective and perceptual change
In a small randomized, double-blind, placebo-controlled crossover study of 32 screened healthy adults, mescaline produced marked changes in subjective experience and perception. This demonstrates a pharmacological effect, not a guaranteed personal, spiritual, or therapeutic benefit [1].
Evidence limit: Controlled acute human evidence; no demonstrated clinical efficacy
Mescaline can raise heart rate, blood pressure, and body temperature and may cause sweating, headache, weakness, impaired coordination, nausea, or vomiting. This matters especially with cardiovascular disease or other medical vulnerability [1][2][4].
Read interaction considerations
Human interaction data are limited. Combining mescaline with other psychoactive, serotonergic, stimulant, or blood-pressure-altering substances could make cardiovascular or psychological effects less predictable; alcohol and sedatives may further impair judgment and coordination. Prescribed antidepressants, antipsychotics, stimulants, migraine medicines, and other drugs may alter effects or risk, but evidence is insufficient to provide a safe combination rule. A qualified clinician or pharmacist should review a complete medication and health history; do not stop prescribed treatment to pursue an experience.
Legal and regulatory context
Legal status varies by country, state, plant species, preparation, and whether conduct is religious, research, or commercial. In the United States, mescaline is federally listed in Schedule I; limited religious exemptions and approved research pathways do not create general permission for recreational or therapeutic use [4]. San Pedro’s legal treatment may differ from peyote and from purified mescaline, and laws can change. Check current official rules where you live before possessing, transporting, cultivating, or facilitating it.